Amphastar Pharmaceuticals
AMPH
108 hedge funds and large institutions have $397M invested in Amphastar Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 42 increasing their positions, 32 reducing their positions, and 14 closing their positions.
31% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 32
29% more capital invested
Capital invested by funds: $307M → $397M (+$90.1M)
1.47% more ownership
Funds ownership: 43.13% → 44.61% (+1.5%)
5% less funds holding
Funds holding: 114 → 108 (-6)
36% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$4.77M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$3.51M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$2.5M |
| 4 |
MAM
Martingale Asset Management
Boston,
Massachusetts
|
+$1.88M |
| 5 |
Renaissance Technologies
New York
|
+$1.69M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fisher Asset Management
Camas,
Washington
|
-$1.99M |
| 2 |
JP Morgan Chase
New York
|
-$1.93M |
| 3 |
Goldman Sachs
New York
|
-$1.4M |
| 4 |
Creative Planning
Overland Park,
Kansas
|
-$1.24M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$865K |
AMPH Hedge Fund Activity: Q3 2018 in Review
108 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Amphastar Pharmaceuticals (AMPH) for Q3 2018, worth a combined $397M — up 29% from $307M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of AMPH and 9 opened new positions — a net loss of 5 holders — while 32 trimmed existing stakes and 42 added.
The largest buyer was BlackRock, adding an estimated $4.77M. The largest seller was Fisher Asset Management, exiting entirely with an estimated $1.99M sold.
- 108 institutional investors held Amphastar Pharmaceuticals (AMPH) as of Q3 2018, down from 114 in Q2 2018.
- Funds reported $397M of Amphastar Pharmaceuticals stock for Q3 2018, up 29% quarter-over-quarter.
- 9 funds opened new Amphastar Pharmaceuticals positions in Q3 2018 and 14 closed out, a net change of -5 holders.
- The largest Amphastar Pharmaceuticals buyer in Q3 2018 was BlackRock, an estimated $4.77M added.
- The largest Amphastar Pharmaceuticals seller in Q3 2018 was Fisher Asset Management, an estimated $1.99M sold.
Based on aggregated 13F filings for Q3 2018.